Patent 6204268 Issued on March 20, 2001. Estimated Expiration Date: April 13, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/254.02, The additional five-membered hetero ring also has chalcogen as a ring member514/64, Boron containing DOAI514/211.15, Additional nitrogen containing hetero ring attached directly or indirectly to the seven-membered hetero ring by nonionic bonding514/217.05, Plural ring hetero atoms in the additional hetero ring514/235.8, Plural ring nitrogens in the additional hetero ring (e.g., imidazole, pyrazine, etc.)514/253.1, The five-membered nitrogen hetero ring has chalcogen as a ring member540/598, Plural hetero atoms in the additional hetero ring544/121, Piperazine ring544/229, Boron or silicon containing544/357, Plural diazine rings544/360, Six-membered ring consisting of one nitrogen and five carbons (e.g., pyridine, etc.)544/363, Quinoline or isoquinoline (including hydrogenated)544/364, At least three hetero rings containing544/368, The five-membered hetero ring is one of the cyclos in a polycyclo ring system544/369, 1,3-oxazole ring or 1,3-thiazole ring (including hydrogenated)544/384, Chalcogen bonded directly to piperazine ring carbon544/385Plural chalcogens bonded directly to piperazine ring carbons
Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
Other References
Gennaro, et al., Eds., "Remington: The Science and Practice of Pharmacy", Mack Printing Company, Easton, Pennsylvania (1995)
Kaiser et al., "Factor Xa Inhibitors as Novel Antithrombotic Agents: Facts and Perspectives," Cardiovascular Drug Reviews, 12(3):225-236 (1994)
Robl, et al., "Dual Metalloprotease Inhibitors. II. Effect of Substitution and Stereochemistry on Benzazepinone Based Mercaptoacetyls," Bioorganic and Medicinal Chemistry Letters 4(15):1795-1800 (1994)
Robl, et al., "Dual Metalloprotease Inhibitors. 6. Incorporation of Bicyclic and Substituted Monocyclic Azepinones as Dipeptide Surrogates in Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitors," Journal of Medicinal Chemistry, 39(2):494-502 (1996)
Semple, et al., "Design, Synthesis, and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-argininal derivatives incorporating P3-4 lactam sulfonamide moieties", J. Med. Chem. 39:4531-4536 (1996)
Skiles, et al., Bioorganic & Medicinal Chemistry Letters, 3(4):773-778 (1993)
Skiles, et al., Chemical Abstracts, vol. 120, No. 11, (1994) (CA: 120:135101a)
Tourwe, et al., "Conformational Restriction of Tyr and Phe Side Chains in Opioid Peptides: Information About Preferred and Bioactive Side-Chain Topology", Biopolymers 38:1-12 (1996)
Almquist et al., "Synthesis and Biological Activity of a Ketamethylene Analogue of a Tripeptide Inhibitor of Angiotensin Converting Enzyme", J. Med. Chem. 23:1392-1398 (1980)
Blankenship et al., "Amino Acid Sequence of Ghilanten: Anticoagulant-Antimetastatic Principle of the South American Leech, Haementeria ghilianii", Biochem, BioPhys. Res. Commun. 166:1384-1389 (1990)
Bodanszky, "The Principles of Peptide Synthesis", Hafner, et al., Eds., Springer-Verlag, Berlin (1984) Book Table of Contents Only
Brankamp et al., "Ghilantens: Anticoagulants Antimetastatic Proteins from the South American Leech, Haementeria ghilianii", J. Lab. Clin. Med. 115:89-97 (1990)
Bundgard, "Design of Pro-drugs", pp. 7-9, Elsevier, Amsterdam, 1985
Bundgard, "Design of Pro-drugs", pp. 21-24, Elsevier, Amsterdam, 1985
Szelke et al., CA:97:39405 (1982)
Cappello et al., "Ancylostoma Factor Xa Inhibitor: Partial Purification and its Identification as a Major Hookworm-derived Anticoagulant in Vitro", J. Infect. Dis. 167:1474-1477 (1993)
Claeson, "Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System", Blood Coag. Fibrinol. 5:411-436 (1994)
Condra et al., "Isolation and Structural Characterization of a Potent Inhibitor of Coagulation Factor Xa from the Leech Haementeria ghilianii" Thromb. Haemost. 61:437-441 (1989)
Cox, "Coagulation Factor X Inhibitor from the Hundred-pace Snake (Deinagkistrodon Acutus) Venom", Toxicon 31:1445-1457 (1993)
Davie et al., "The Coagulation Cascade: Initiation, Maintenance and Regulation", Biochemistry 30:10363-10370 (1991)
Diana, et al., "Picornavirus Inhibitors: Trifluoromethyl Substitution Provides a Global Protective Effect against Hepatic Metabolism", J. Med. Chem. 38:1355-1371 (1995)
Diana, et al., "Oxadiazaoles as Ester Bioisosteric Replacements in Compounds Related to Disoxaril. Antirhinovirus Activity", J. Med. Chem. 37:2421-2436 (1994)
DiMaio et al., "Synthesis of Chiral Piperazin-2-ones as Model Peptidomimetics", J. Chem. Soc. Perkins. Trans. I, 1687-1689 (1989)
Edwards et al., "Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl -Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole", J. Am. Chem. Soc. 114:1854-1863 (1992)
Edwards et al., "Peptidyl -Ketoheterocyclic Inhibitors of Human Neutrophil Elastase. 2. Effect of Varying the Heterocyclic Ring on in Vitro Potency", J. Med. Chem. 38:76-85 (1995)
Girard et al., "Functional Significance of the Kunitz-type Inhibitory Domains of Lipoprotein-associated Coagulation Inhibitor", Nature 338:518-520 (1989)
Gross et al., Eds., "The Peptides: Analysis, Synthesis, Biology", Academic Press, vol. 3 (1981) Book Table of Contents Only
Udenfriend et al., Eds., "The Peptides: Analysis, Synthesis, Biology", Academic Press, vol. 9 (1977) Book Table of Contents Only
Hann, J. Chem. Soc. Perkins. Trans. I, pp. 307-314 (1982)
Hauptmann et al., "Comparison of the Anticoagulant and Antithrombotic Effects of Synthetic Thrombin and Factor Xa Inhibitors", Thromb. Haemost. 63:220-223 (1990)
Hitomi et al., "Inhibitory Effect of New Synthetic Protease Inhibitor (FUT-175) on the Coagulation System", Haemostatsis 15:164-168 (1985)
Hollenbach et al., "A Comparative Study of Prothrombinase and Thrombin Inhibitors in a Novel Rabbit Model of Non-Occlusive Deep Vein Thrombosis", Thromb. Haemost. 71:357-362 (1992)
Holladay et al., "Synthesis of Hydroxyethylene and Ketomethylene Dipeptide Isosteres", Tetrahedron Lett. 24:4401-4404 (1983)
Hruby, "Conformational Restrictions of Biologically Active Peptides via Amino Acid Side Chain Groups", Life Sci. 31:189-199 (1982)
Hudson, et al., "Methionine Enkephalin and Isosteric Analogues", Int. J. Pept. Prot. Res. 14:177-185 (1979)
Jacobs et al., "Isolation and Characterization of a Coagulation Factor Xa Inhibitor from Black Fly Salivary Glands", Thromb. Haemost. 64:235-238 (1990)
Jennings-White et al., "Synthesis of Ketomethylene Anaolgs of Dipeptides", Tetrahedron Lett. 23:2533-2534 (1982)
Kam et al., "Mechanism-based Isocoumarin Inhibitors for Trypsin and Blood Coagulation Serine Proteases: New Anticoagulants", Biochemistry 27:2547-2557 (1988)
Kojima et al., "Preparations, Solution Conformations and Molecular Structures of N, N'-Ethylene-bridged Dipeptides and their Derivatives", Int. J. Peptide Protein Res. 37:468-475 (1991)
Mann, et al., "Surface-Dependent Reactions of the Vitamin K-Dependent Enzyme Complexes", Blood 76:1-16 (1990)
Morley, "Modulation of the Action of Regulatory Peptides by Structural Modification", (General Review) Trends Pharm. Sci. pp. 463-468 (1980)
Nagahara et al., "Dibasic (Amidinoaryl)propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors", J. Med. Chem. 37:1200-1207 (1994)
Nutt et al., "The Amino Acid Sequence of Antistasin: A Potent Inhibitor of Factor Xa Reveals a Repeated Internal Structure", J. Biol. Chem. 263:10162-10167 (1988)
Seymour et al., "Ecotin Is A Potent Anticoagulant and Reversible Tight-binding Inhibitor of Factor Xa", Biochemistry 33:3949-3958 (1994)
Silverman, "The Organic Chemistry of Drug Design and Drug Action", pp. 352-401, Academic Press, San Diego, CA. (1992)
Sinha et al., "Effect of Gamma Carboxylation on Prothrombinase Inhibitory Activity of Catalytically Inactive Factor Xa", Thromb. Res. 75:427-436 (1994)
Spatola et al., "Structure-Activity Relationship of Enkephalins Containing Serially Replaced Thiomethylene Amide Bond Surrogates", Life Sci. 38:1243-1249 (1986)
Spatola, "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins", (General Review), B. Weinstein, Eds., Marcell Decker, New York, p. 260. (1983)
Sturzebecher et al., "Synthetic Inhibitors of Bovine Factor Xa and Thrombin. Comparison of Their Anticoagulant Efficiency", Thromb. Res. 54:245-252 (1989)
Tidwell et al., "Strategies for Anticoagulation with Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors", Thromb. Res. 19:339-349 (1980)
R. Tomatis, et al., "Synthesis and pharmacological activity of Leu-Enkephalins modified at Gly 2 -Gly 3 nitrogens," European Journal of Medicinal Chemistry--Chimica Therapeutica, vol. 16, No. 3, pp. 229-232 (1981)
Turner et al., "p-Amidino Esters as Irreversible Inhibitors of Factor IXa and Xa and Thrombin", Biochemistry 25:4929-4935 (1986)
Tsutsumi, et al., "Synthesis and Structure-Activity Relationships of Peptidyl -Keto Heterocycles as Novel Inhibitors of Prolyl Endopeptidase", J. Med. Chem. 37:3492-3502 (1994)
Waxman et al., "Tick Anticoagulant Peptide (Tap) Is a Novel Inhibitor of Blood Coagulation Factor Xa", Science 248:593-596 9 (1990)
Wityak, et al., "Synthesis of Thrombin Inhibitor DuP 714", J. Org. Chem. 60:3717-3722 (1995)
Stilz et al., "Discovery Of An Orally Active Non-Peptide Fibrinogen Receptor Antagonist", J. Med. Chem., vol. 39, No. 11, pp. 2118-2122 (1996)
Kunitada et al., "Factor Xa Inhibitors", Current Pharmaceutical Design, vol. 2, No. 5, pp. 531-542 (1996
April 13, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
